ProCE Banner Activity

Breaking Down the Headlines: Addressing the Buzz Around Incretin-Based Therapies With Patients

Podcast Episodes

Listen as expert faculty break down the latest headlines on incretin-based therapies and how to address these topics with patients.

Released: February 09, 2024

Share

Faculty

Jennifer B Green

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Carol Hatch Wysham

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Provided by

Provided by Clinical Care Options, LLC in partnership with Endocrine Society

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Jennifer Green, MD: consultant/advisor/speaker: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, NovoNordisk, Pfizer, Valo, Vertex; researcher: Boehringer Ingelheim, Lilly, Merck, Roche.

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Carol Hatch Wysham, MD: consultant/advisor/speaker: Abbott, Biomea. researcher: Corcept, Bayer, Eli Lilly, Novo Nordisk, Regeneron, Vanda.